Neuromelanin's role in damage to locus coeruleus cells in Alzheimer's
Contribution of neuromelanin to selective vulnerability of locus coeruleus neurons in Alzheimer's disease
This project looks at whether a natural brain pigment called neuromelanin makes certain locus coeruleus cells more likely to develop Alzheimer-related damage and symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11297514 on NIH RePORTER |
What this research studies
From your perspective, researchers want to know why the tiny locus coeruleus (LC) cells are among the first to show Alzheimer-related tau and later die. Because mice do not naturally make neuromelanin, the team uses a viral tool that forces mouse neurons to produce human-like neuromelanin so they can watch whether those neurons become vulnerable. They combine cellular and tissue studies with neuromelanin-sensitive MRI and behavior tests tied to sleep, mood, and thinking to link LC changes to early Alzheimer symptoms. The goal is to connect the pigment, neuron health, and early signs so new biomarkers or protective strategies can be identified.
Who could benefit from this research
Good fit: People with early Alzheimer's disease, mild cognitive impairment, or older adults willing to undergo neuromelanin-sensitive MRI or donate brain tissue would be most relevant to this work.
Not a fit: Patients whose dementia is caused by non‑Alzheimer conditions or those with very advanced Alzheimer's are unlikely to gain direct benefit from this basic-mechanism project in the near term.
Why it matters
Potential benefit: If successful, this work could reveal why LC neurons fail in Alzheimer's and point to earlier biomarkers or new ways to protect those neurons.
How similar studies have performed: Prior human imaging studies have detected LC changes with neuromelanin-sensitive MRI, but making neuromelanin in mice with human tyrosinase to test causality is a novel approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Weinshenker, David — Emory University
- Study coordinator: Weinshenker, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.